Acquisition Brings Parkinson’s Treatment to Lundbeck

The signing of a definitive agreement, that will see international pharmaceutical business H. Lundbeck A/S acquire Prexton Therapeutics BV, will bring a potential candidate for treatment of Parkinson’s to the Danish company. Under terms of the agreement, Lundbeck will pay €100 million upfront plus €805 million in development and sales milestones.

It will obtain global rights for foliglurax, which is currently in clinical phase II testing for the symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (uncontrolled movements) including Levodopa Induced Dyskinesia (LID). First data from the ongoing clinical phase II program is expected to be available in mid-2019.

"We are very excited to be working with Lundbeck, a company with a strong history and focus on diseases of the central nervous system," said François Conquet, Ph.D, founder and chief executive Officer, of Netherlands-based Prexton. "Lundbeck shares our vision for the development of foliglurax to help patients living with Parkinson’s disease.”